CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug Administration for sickle cell disease. It's a turning point for the business, which now has its first approved product.

But what's next for the business, and where does CRISPR Therapeutics go from here? Below I'll look at where the company may be in five years, and whether it's a good time to invest in the stock.

The CRISPR gene-editing market is expected to be worth $14.8 billion by 2030, according to projections from Straits Research. The industry is growing at an incredibly fast compound annual rate of 29.8%. And amid its early growth, CRISPR is starting to establish itself as a big name in gene editing. It's not a huge market, but CRISPR has the potential to become an early market leader within it. 

Continue reading

Source Fool.com